However, the specific nature of this interference remains unknown. 9 demonstrated that suramin interferes with viral entry into Vero E6 and human airway epithelial cells. 8 discovered that one such compound, suramin, inhibited RNA-dependent RNA polymerase (RdRp) by preventing binding of the RdRp with the RNA template, blocking viral replication. Drug repositioning is another potential strategy for the discovery of non-protein, broad-spectrum therapeutic candidates. Protein-based approaches based on angiotensināconverting enzyme 2 (ACE2) receptor mimicry include antibodies 5, de novo minibinders 6, and multivalent versions of designed minibinders 7. For these reasons, broadly neutralizing therapeutics are of interest in combating existing and emerging SARS-CoV-2 variants. SARS-CoV-2 variants continue to emerge due to increased mutational pressures from susceptible populations 1 and immune evasion 2 making natural immunity 3 and existing vaccines less effective 4, resulting in breakthrough infections.
0 Comments
Leave a Reply. |